Drugs / Rabeprazole ER
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT00839306 | Aug 2008 → Aug 2009 | gastroesophageal reflux disease | Eisai Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Rabeprazole ER | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00839306 ↗ |
| Route | Oral | “50 mg capsule, taken orally, once daily for 26 weeks.” NCT00839306 ↗ |